Just the Facts on ACADIA Pharmaceuticals Inc. (ACAD)

ACADIA Pharmaceuticals Inc. (ACAD) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $18.50, down from yesterday’s close by -0.43%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.

Fundamental Analysis

ACADIA Pharmaceuticals Inc. (ACAD) currently trades with a market capitalization of $2.31 Billion. That value represents a market adjusting for revenues that have been growing by 219.69 % on a quarterly year/year basis as of the company’s last quarterly report.

You can get a sense of how sustainable that is by a levered free cash flow of -$193.2 Million over the past twelve months. Generally speaking, earnings are expected to grow in coming quarters. Analysts are forecasting earnings of -$0.56 on a per share basis this quarter. Perhaps, that suggests something about why 0.45% of the outstanding share supply is held by institutional investors.

Technical Analysis

We’ve taken a serious look at this stock from a fundamental perspective, but the tale of the tape may offer more hints about what lies under the surface. Looking at the stock’s movement on the chart, ACADIA Pharmaceuticals Inc. recorded a 52-week high of $41.20. It is now trading 22.7% off that level. The stock is trading $20.60 its 50-day moving average by 2.1%. The stock carved out a 52-week low down at $14.51.

In recent action, ACADIA Pharmaceuticals Inc. (ACAD) has made a move of -7.41% over the past month, which has come on Strong relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 14.61, and it’s gotten there by action that has been more volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 10.73% with $124.36 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of ACAD.

Previous articleThe Case for and Against The Estee Lauder Companies Inc. (EL)
Next articleTaking a Look at the Data Behind Amgen Inc. (AMGN)